Integer (NYSE:ITGR) Hits New 52-Week High – Time to Buy?

Integer Holdings Co. (NYSE:ITGR) hit a new 52-week high during trading on Tuesday . The stock traded as high as $140.91 and last traded at $140.20, with a volume of 3497 shares changing hands. The stock had previously closed at $139.49.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Truist Financial lowered their price target on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Oppenheimer assumed coverage on Integer in a report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 target price for the company. Bank of America upped their price target on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Piper Sandler reiterated an “overweight” rating and set a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. Finally, KeyCorp upped their price target on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and an average target price of $139.75.

Integer Stock Down 0.7 %

The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The firm has a 50 day simple moving average of $128.63 and a 200-day simple moving average of $122.07. The stock has a market capitalization of $4.64 billion, a price-to-earnings ratio of 43.09, a price-to-earnings-growth ratio of 1.96 and a beta of 1.09.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. During the same period last year, the company posted $1.27 earnings per share. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, sell-side analysts forecast that Integer Holdings Co. will post 5.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC lifted its holdings in shares of Integer by 7.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 10,013 shares of the medical equipment provider’s stock valued at $1,168,000 after purchasing an additional 725 shares in the last quarter. Texas Permanent School Fund Corp lifted its stake in Integer by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 29,167 shares of the medical equipment provider’s stock valued at $3,403,000 after acquiring an additional 377 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Integer by 43.5% during the 1st quarter. SG Americas Securities LLC now owns 8,394 shares of the medical equipment provider’s stock worth $979,000 after purchasing an additional 2,544 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Integer during the 1st quarter worth approximately $106,000. Finally, QRG Capital Management Inc. increased its holdings in shares of Integer by 1.1% during the 1st quarter. QRG Capital Management Inc. now owns 31,368 shares of the medical equipment provider’s stock worth $3,660,000 after acquiring an additional 332 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.